Chronic Effect of Combined Treatment With Omapatrilat and Adrenomedullin on the Progression of Heart Failure in Rats

American Journal of Hypertension

Volumn 19, Issue 10, 2006, Pages 1039-1048

  Nishikimi, Toshio ^a   Mori, Yosuke ^a   Ishimura, Kimihiko ^a   Ishikawa, Yayoi ^a   Koshikawa, Shogo ^a   Akimoto, Kazumi ^a   Minamino, Naoto ^b   Kangawa, Kenji ^b   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Adrenomedullin; atrial natriuretic peptide; heart failure; oxidative stress; vasopeptidase inhibitor

Indexed keywords

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; OMAPATRILAT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEMODYNAMICS; HISTOLOGY; LONG TERM CARE; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RAT; TREATMENT OUTCOME;

ADRENOMEDULLIN; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIAC OUTPUT, LOW; COLLAGEN; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HEART VENTRICLES; INTERCELLULAR ADHESION MOLECULE-1; MALE; NADPH OXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDINES; RATS; RATS, INBRED DAHL; RNA, MESSENGER; THIAZEPINES; TRANSFORMING GROWTH FACTOR BETA;

EID: 33749251093     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.02.013     Document Type: Article

References (32)

1. Samson W.K. Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 61 (1999) 363-389
2. Nishikimi T., Yoshihara F., Mori Y., Kangawa K., and Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res 26 (2003) S121-S127
3. Nicholls M.G., Charles C.J., Lainchbury J.G., Lewis L.K., Rademaker M.T., Richards A.M., and Yandle T.G. Adrenomedullin in heart failure. Hypertens Res 26 (2003) S135-S140
4. Rademaker M.T., Charles C.J., Lewis L.K., Yandle T.G., Cooper G.J., Coy D.H., Richards A.M., and Nicholls M.G. Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 96 (1997) 1983-1990
5. Nagaya N., Nishikimi T., Horio T., Yoshihara F., Kanazawa A., Matsuo H., and Kangawa K. Cardiovascular and renal effects of adrenomedullin in rats with heart failure. Am J Physiol 276 (1999) R213-R218
6. Lainchbury J.G., Nicholls M.G., Espiner E.A., Yandle T.G., Lewis L.K., and Richards A.M. Bioactivity and interactions of adrenomedullin and brain natriuretic peptide in patients with heart failure. Hypertension 34 (1999) 70-75
7. Nagaya N., Satoh T., Nishikimi T., Uematsu M., Furuichi S., Sakamaki F., Oya H., Kyotani S., Nakanishi N., Goto Y., Masuda Y., Miyatake K., and Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 101 (2000) 498-503
8. Nishikimi T., Yoshihara F., Horinaka S., Kobayashi N., Mori Y., Tadokoro K., Akimoto K., Minamino N., Kangawa K., and Matsuoka H. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension 42 (2003) 1034-1041
9. Jiang W., Jiang H.F., Pan C.S., Cai D.Y., Qi Y.F., Pang Y.Z., and Tang C.S. Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats. Hypertens Res 27 (2004) 109-117
10. Lisy O., Jougasaki M., Schirger J.A., Chen H.H., Barclay P.T., and Burnett Jr. J.C. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 275 (1998) F410-F414
11. Rademaker M.T., Charles C.J., Cooper G.J., Coy D.H., Espiner E.A., Lewis L.K., Nicholls M.G., and Richards A.M. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension 39 (2002) 93-98
12. Ishimura K., Nishikimi T., Akimoto K., Ono H., Kangawa K., and Matsuoka H. Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats. J Hypertens 23 (2005) 2287-2296
13. Sagnella G.A. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone 3 (2002) 90-95
14. Nishikimi T., Tadokoro K., Akimoto K., Mori Y., Ishikawa Y., Ishimura K., Horio T., Kangawa K., and Matsuoka H. Response of adrenomedullin system to cytokine in cardiac fibroblasts-role of adrenomedullin as an antifibrotic factor. Cardiovasc Res 66 (2005) 104-113
15. Chini E.N., Chini C.C., Bolliger C., Jougasaki M., Grande J.P., Burnett Jr. J.C., and Dousa T.P. Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. Kidney Int 52 (1997) 917-925
16. Shimosawa T., Shibagaki Y., Ishibashi K., Kitamura K., Kangawa K., Kato S., Ando K., and Fujita T. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 105 (2002) 106-111
17. Nishikimi T., Mori Y., Kobayashi N., Tadokoro K., Wang X., Akimoto K., Yoshihara F., Kangawa K., and Matsuoka H. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 39 (2002) 1077-1082
18. Mori Y., Nishikimi T., Kobayashi N., Ono H., Kangawa K., and Matsuoka H. Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension 40 (2002) 107-113
19. Nishikimi T., Horio T., Sasaki T., Yoshihara F., Takishita S., Miyata A., Matsuo H., and Kangawa K. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension 30 (1997) 1369-1375
20. Ohta H., Tsuji T., Asai S., Tanizaki S., Sasakura K., Teraoka H., Kitamura K., and Kangawa K. A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Clin Chim Acta 287 (1999) 131-143
21. Kobayashi N., Mori Y., Nakano S., Tsubokou Y., Shirataki H., and Matsuoka H. Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 19 (2001) 795-801
22. Nishikimi T., Miyata A., Horio T., Yoshihara F., Nagaya N., Takishita S., Yutani C., Matsuo H., Matsuoka H., and Kangawa K. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 279 (2000) H3031-H3039
23. Tsuruda T., Kato J., Kitamura K., Kuwasako K., Imamura T., Koiwaya Y., Tsuji T., Kangawa K., and Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 31 (1998) 505-510
24. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs 63 (2003) 2185-2202
25. Kaikita K., Fogo A.B., Ma L., Schoenhard J.A., Brown N.J., and Vaughan D.E. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104 (2001) 839-844
26. Troughton R.W., Rademaker M.T., Powell J.D., Yandle T.G., Espiner E.A., Frampton C.M., Nicholls M.G., and Richards A.M. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension 36 (2000) 523-530
27. Cataliotti A., Boerrigter G., Chen H.H., Jougasaki M., Costello L.C., Tsuruda T., Lee S.C., Malatino L.S., and Burnett Jr. J.C. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 105 (2002) 639-644
28. Kuwahara F., Kai H., Tokuda K., Niiyama H., Tahara N., Kusaba K., Takemiya K., Jalalidin A., Koga M., Nagata T., Shibata R., and Imaizumi T. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 41 (2003) 819-823
29. Millette E., Demeilliers B., Wu R., Laplante M.A., El Midaoui A., Moreau P., Lamontagne D., and de Champlain J. Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. J Hypertens 21 (2003) 125-135
30. Chao J., Kato K., Zhang J.J., Dobrzynski E., Wang C., Agata J., and Chao L. Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides 22 (2001) 1731-1737
31. Tsuruda T., Kato J., Hatakeyama K., Masuyama H., Cao Y.N., Imamura T., Kitamura K., Asada Y., and Eto T. Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats. Cardiovasc Res 65 (2005) 921-929
32. Meier P., Maillard M., and Burnier M. The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 15-30